eResearchTechnology Announces $13.5 Million in July Study Awards for Cardiac Safety Monitoring and Information Distribution Serv
July 27 2005 - 5:05PM
PR Newswire (US)
eResearchTechnology Announces $13.5 Million in July Study Awards
for Cardiac Safety Monitoring and Information Distribution Services
Early Third Quarter Visibility to Significant Sponsor Commitments
Indicates Increased Traction, Including Two Program Awards and Two
Thorough QT Studies PHILADELPHIA, July 27 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), a leading provider
of centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has been awarded
more than $13.5 million in cardiac safety monitoring and services
to date in July 2005. Highlights of these collective awards
include: -- Two later phase programs from a top 10 global
pharmaceutical company totaling more than $7.8 million and
comprising a number of studies with a massively distributed
investigator network that spans more than 750 sites. -- Two
Thorough QT studies to be completed in the manual methodology
totaling more than $3 million sponsored by a growing focused
pharmaceutical organization and an emerging biopharmaceutical
targeting innovative anti-infective therapies. eRT will provide
comprehensive support, including provision of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data
that is subsequently provided to eRT for analysis. eRT will perform
digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT(R) workflow
enabled data handling technology, the first solution in production
that was designed explicitly to meet emerging international
regulatory guidance and technical standards. In other news released
separately today, eRT announced a strategic alliance with Mortara
Instrument to provide enhanced digital ECG products and services.
The agreement includes production of an eRT private label device
and authorized reseller rights for equipment and Mortara's E-Scribe
ECG Warehouse Services to the global drug development industry.
"Substantial early traction in the third quarter indicates growing
momentum in the trends toward program awards and the drug
development industry's embrace of key elements of ICH, E14
regulatory guidance, which require Thorough QT studies for
virtually all new compounds," said Scott Grisanti, senior vice
president of business development and chief marketing officer at
eRT. "Our key July wins illustrate two of eRT's most distinguishing
strengths. First, sponsors recognize eRT's overall capacity and
logistics capabilities, key to supporting extensive later phase
programs comprising hundreds of sites, as an important core
competency. Second, eRT's ongoing scientific, technical and
operational expertise in the extraordinarily demanding Thorough QT
Study arena continues to drive awards in this critical market
segment. "We were very pleased with industry response to our
June-July seminar series, which focused on practical implications
of ICH, E14 and planning and conduct of Thorough QT studies. We
hosted a total of about 300 attendees at three sessions in London,
Tokyo and Philadelphia and are adding a date in Orange County,
Calif. in October to meet demand from the West Coast
biopharmaceutical community. In addition, the enhancement of our
Mortara relationship supports delivery of innovative products and
services that help sponsors to optimize their cardiac safety
programs enterprise-wide." Based in Philadelphia, PA,
eResearchTechnology, Inc. (http://www.ert.com/) is a provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The
sponsors may cancel these agreements at their sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci of
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden of
Hayden Communications, +1-858-704-5065, for eRT Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024